Clinical Trial Update: Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of MGY825 in patients with advanced non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MGY825

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: TERMINATED